Fizazi, et al. ARAMIS: Efficacy and safety of darolutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC). ASCO-GU 2019, abstract 140.
Adjuvante behandeling pancreascarcinoom: FOLFIRINOX of gemcitabine?
mrt 2019 | Maag-darm-leveroncologie